Private firm suspended for conducting clinical trials on poor women

Anti-cancer drug was given to poor women without their consent

sonal

Sonal Matharu | June 24, 2011



The drugs controller general of India (DCGI) under the health ministry on Friday suspended the approval of a private firm conducting clinical trials in Hyderabad after it was found that the firm is administering anti-cancer drug to poor women in Piduguralla town of Andhra Pradesh without securing their informed consent.

Investigations conducted by the DCGI’s south zone office in Chennai and sub-zonal office in Hyderabad on June 20 and 21, 2011 have confirmed that M/s Axis Clinicals Ltd., Hyderabad, did not follow rules with respect to subject recruitment process, informed consent process, independence of the ethics committee and its review and decision making process.

The investigations were conducted on at the Bio-equivalence study centre of M/s Axis Clinicals Ltd. situated at Serlingampally, Miyapur, Hyderabad. It was found that the company was violating norms specified in schedule Y of the drugs and cosmetics rules for conducting clinical trials.

“The DCGI has therefore suspended the approval of the said firm for conducting all Bio-availability and Bio-equivalence studies at their centres in Miyapur, Hyderabad in public interest,” said a press note from the health ministry.

The office of the DCG(I) has further decided to investigate the working of all Bio-availability and Bio-equivalence study centres in Andhra Pradesh within a period of two months to ensure that such studies are performed strictly in accordance with the applicable regulatory provisions and prescribed guidelines.

M/s Axis Clinicals Ltd., Hyderabad had conducted Bio-equivalence studies on Exemestane tablets in its Serlingampally, Miyapur, Hyderabad centre during the period 27th January 2011 to 15th February 2011.
 

Comments

 

Other News

Dharmendra Pradhan tenders resignation

Dharmendra Pradhan, education minister at the centre of the storm of the NEET paper leak, offered his resignation to the prime minister on Saturday.   He posted a two-page letter on X, saying he was pained by the events of the last ten days. "This is not a matter of personal

Cabinet approves scheme of chemical parks

The union cabinet chaired by the PM has approved Bharat Audyogik Vikas Yojana Rasayan or BHAVYA - Rasayan Scheme for establishing three dedicated Chemical Parks in the country. The Scheme was announced in the Union Budget of FY 2026–27.   The Scheme will have a total financ

Anurag Jain, IAS appointed as Chief Executive Officer, NITI Aayog

 Anurag Jain, a 1989-batch IAS officer of the Madhya Pradesh cadre, has been appointed as the Chief Executive Officer (CEO) of NITI Aayog for a two-year term after serving as the Chief Secretary of Madhya Pradesh. A distinguished administrator with extensive experience in infrastructure, industrial de

Shri Ashok Barnwal, IAS has been appointed as the Chief Secretary of Madhya Pradesh

 Ashok Barnwal, a 1991-batch IAS officer of the Madhya Pradesh cadre, has been appointed as the Chief Secretary of Madhya Pradesh, succeeding Anurag Jain following his appointment as CEO of NITI Aayog. Prior to assuming the state`s top bureaucratic position, Barnwal served as Additional Chief Secretar

PM announces fast-track courts for paper leak cases

Prime minister Narendra Modi on Thursday stated that the government has decided to set up fast-track courts to ensure swift and stringent punishment for those involved in paper leaks. Emphasising that nothing is more important than the welfare and future of the youth, he noted that h

Making India’s textile & apparel sector sustainable

India’s textile and apparel sector sits at the heart of the economy but is constrained by traditional manufacturing approach. It contributes close to 2% of GDP and around 11% of manufacturing gross value added, with GDP share expected to reach 5% by the end of the decade. The sector employs around 45

Upcoming Conferences





Archives

Current Issue

Opinion

Facebook Twitter Google Plus Linkedin Subscribe Newsletter

Twitter